Latest News
Priothera Receives R&D Innovation Loan from Bpifrance
€1.5 million loan will further support clinical manufacture of mocravimod…
Priothera presents at EBMT conference March 20-23
Priothera presents at EBMT conference March 20-23
Location, location, location: fighting hematological malignancies by trapping T cells in lymphoid tissue
Priothera’s small molecule mocravimod is transforming the prospects…
Priothera – FDA and EMA Grant Orphan Drug Designation to mocravimod for the treatment of Acute Myeloid Leukemia (AML) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)
Priothera – FDA and EMA Grant Orphan Drug Designation to mocravimod…
Priothera Enters Loan Agreement of €17.5 Million with the European Investment Bank
Loan will further support the conduct of a global registration-enabling…
Priothera Appoints Elisabeth Kueenburg M.D., as Chief Medical Officer
Dr. Kueenburg, former Clinical Development Lead at Celgene, a Bristol Myers Squibb…
Biocentury
Priothera raises €30 million to develop onetime Novartis candidate in AML transp…
Press Release
Priothera Limited (priothera.com) has successfully closed a Series A financing…